The project focuses on the development of a therapeutic strategy to reactivate macrophages within tumours. The immunosuppressive environment created by the tumor will direct macrophages towards a pro-tumoral phenotype. They will then participate in the growth of the tumour by acting directly on cancer cells but also by suppressing cytotoxic responses of T lymphocytes, so they are a key element of the tumour environment. The challenge is to find a way to counteract this immunosuppression and reactivate macrophages. The strategy is to use a proprotein convertase inhibitor in combination with a TLR receptor ligand to reactivate tumor macrophages within gliomes.